Hologic director awarded 3,190 restricted stock units
Madaus Martin D reported acquisition or exercise transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Madaus Martin D reported acquisition or exercise transactions in this Form 4 filing.
Hologic director Martin D. Madaus reported an equity award of 3,190 restricted stock units of common stock on February 26, 2026. These units vest on the date of the 2027 Annual Meeting of Stockholders and are settled one-for-one in Hologic common shares.
After this grant, Madaus directly holds 5,396 common shares. A separate line shows indirect ownership of 5,445 common shares through a revocable trust, reflecting his holdings in that entity.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 3,190 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
Footnotes (2)
- F1. Represents restricted stock units which vest on the date of the 2027 Annual Meeting of Stockholders and are settled in shares of common stock.
- F2. Restricted stock units are settled in shares of common stock on a one-for-one basis.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Hologic (HOLX) report for Martin D. Madaus?
When do Martin D. Madaus’s new Hologic (HOLX) restricted stock units vest?
How are the Hologic (HOLX) restricted stock units held by Martin D. Madaus settled?
What indirect Hologic (HOLX) holdings does Martin D. Madaus report through a revocable trust?
Is the Hologic (HOLX) Form 4 for Martin D. Madaus a stock purchase or sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.